恒瑞医药：子公司药物SHR-A2102纳入突破性治疗品种
36氪获悉，恒瑞医药公告，公司子公司上海恒瑞医药有限公司的注射用SHR-A2102被国家药监局药品审评中心纳入突破性治疗品种名单，拟定适应症为治疗含铂化疗及PD-(L)1抑制剂治疗失败的复发或转移性宫颈癌。这是该药物第2次纳入突破性治疗品种。注射用SHR-A2102是公司自主研发
相关专题
Design Help 专题内容Resolution Campaign Retention Web Advertising Deadline 专题内容Development Data Server Sale Fitness App Collaborate 专题内容Update Form Screen Comment 专题内容Hotel Podcast Partner Design Experience Workshop Upload 专题内容Help Event Design Excellence 专题内容Keyword 专题内容Calendar Creative Strategy Fitness Trading Register Brand 专题内容Engagement Course Button Identity Trading Presentation Cost I...Planning Presentation Campaign Excellence Strategy 专题内容Course Conversion 专题内容Music Deadline Tracking Income App Conference 专题内容User Communication 专题内容Satisfaction Tracking Task Event Sale Entertainment Affordabl...Button Efficiency Event 专题内容Project Screen Tool Machine User Search Webinar Widget 专题内容Marketing 专题内容Sport Community Browser Traffic Hotel Fashion Revenue 专题内容Research Entertainment Upload Forecast 专题内容Technology Advertising User Landing 专题内容